Literature DB >> 28283439

Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica.

Akiyuki Uzawa1, Masahiro Mori2, Hiroki Masuda2, Ryohei Ohtani2, Tomohiko Uchida2, Setsu Sawai3, Satoshi Kuwabara2.   

Abstract

BACKGROUND: Elevation of cerebrospinal fluid (CSF) interleukin (IL)-6 has been reported in various neurological disorders but has never been systematically analyzed. Our main objectives are to compare the CSF IL-6 levels among various neurological disorders and to evaluate the significance of CSF IL-6 measurements for the diagnosis of neuromyelitis optica (NMO).
METHODS: We retrospectively investigated the IL-6 levels of 572 consecutive CSF samples in patients with various neurological disorders. Additionally, the associations between clinical manifestations in NMO patients and CSF IL-6 levels were closely investigated.
RESULTS: Among the neurological disorders, patients with NMO had the highest CSF IL-6 level. Receiver operating characteristic analysis found the optimal cutoff CSF IL-6 value for diagnosing NMO as 7.8pg/ml, and the sensitivity and specificity were 0.7317 and 0.7694, respectively. In NMO, CSF IL-6 levels were correlated with the length of the spinal cord lesion and anti-aquaporin-4 antibody-positivity and decreased after treatment.
CONCLUSION: CSF IL-6 can be high in various inflammatory and non-inflammatory CNS disorders, but its upregulation appears to be the most remarkable in NMO.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Cerebrospinal fluid; Cutoff; Interleukin-6; Neuromyelitis optica

Mesh:

Substances:

Year:  2017        PMID: 28283439     DOI: 10.1016/j.cca.2017.03.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

Review 1.  Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.

Authors:  Sean J Pittock; Anastasia Zekeridou; Brian G Weinshenker
Journal:  Nat Rev Neurol       Date:  2021-10-28       Impact factor: 42.937

Review 2.  SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation.

Authors:  Madison MacDougall; Jad El-Hajj Sleiman; Philippe Beauchemin; Manu Rangachari
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

3.  Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.

Authors:  Itay Lotan; Richard McGowan; Michael Levy
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 4.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

5.  Interleukin-6, S-Nitrosothiols, and Neurodegeneration in Different Central Nervous System Demyelinating Disorders: Is There a Relationship?

Authors:  Vera Fominykh; Anna Vorobyeva; Mikhail V Onufriev; Lev Brylev; Maria N Zakharova; Natalia V Gulyaeva
Journal:  J Clin Neurol       Date:  2018-05-31       Impact factor: 3.077

6.  Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases.

Authors:  Livia S Hofer; Sara Mariotto; Sebastian Wurth; Sergio Ferrari; Chiara R Mancinelli; Rachele Delogu; Salvatore Monaco; Alberto Gajofatto; Carmen Schwaiger; Kevin Rostasy; Florian Deisenhammer; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-05-15

Review 7.  Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.

Authors:  Kazuo Fujihara; Jeffrey L Bennett; Jerome de Seze; Masayuki Haramura; Ingo Kleiter; Brian G Weinshenker; Delene Kang; Tabasum Mughal; Takashi Yamamura
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-08-20

Review 8.  A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Mohammad Taheri
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

9.  Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.

Authors:  Michael Levraut; Cassandre Landes; Lydiane Mondot; Mikael Cohen; Saskia Bresch; Vesna Brglez; Barbara Seitz-Polski; Christine Lebrun-Frenay
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

10.  Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder.

Authors:  Haoxiao Chang; Hengri Cong; Huabing Wang; Li Du; De-Cai Tian; Yuetao Ma; Yun Xu; Yupeng Wang; Linlin Yin; Xinghu Zhang
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.